Andrew Harrison
Research Subjects
Research Interests
Andrew Harrison has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- R. Grant Steen
Dept. of Orthopaedic Surgery, Louisiana State University Medical Center, New Orleans, LA, United States
2 shared publications - Samir Mehta
Department of Orthopaedic Surgery, University of Pennsylvania, Philadelphia, Pennsylvania
2 shared publications Tawana Wester
Research and Development, Bioventus LLC, Durham, NC 27703, USA
2 shared publicationsAlastair S.E. Younger
Professor, Department of Orthopaedics, University of British Columbia, Vancouver, Canada
1 shared publicationAndrea Veljkovic
Associate Clinical Professor, Department of Orthopaedics, University of British Columbia, Vancouver, Canada
1 shared publicationAnsar Mahmood
Department Trauma & Orthopaedic Surgery, Queen Elizabeth Hospital, Birmingham, UK
1 shared publication
Latest Publications
- Open Access
- 1 December 2022
- Published by Bioscientifica in EFORT Open Reviews
- Vol. 7 (12) , 817-826
Instructional review of key factors to achieve successful outcomes when using low-intensity pulsed ultrasound in fracture repair
Low-intensity pulsed ultrasound (LIPUS) treatment of fractures has been available to the orthopaedic community for nearly three decades; however, it is still considered an experimental treatment by some clinicians, even though there is a wealth of clinical data. Based on the evaluation of clinical trial data, we have established key criteria which can lead to LIPUS success and avoid failure. These are fracture gap size and stability, accurate transducer placement and minimum treatment number. However, from a clinician’s view, the correct attitude to treatment must be observed, and this has also been discussed. It is hoped, armed with this new evaluation of the clinical data, that clinicians can treat patients with LIPUS more effectively, resulting in fewer failures of treatment.
- 1 December 2022
- Published by Bioscientifica in EFORT Open Reviews
- Vol. 7 (12) , 817-826
Open AccessInstructional review of key factors to achieve successful outcomes when using low-intensity pulsed ultrasound in fracture repair
Low-intensity pulsed ultrasound (LIPUS) treatment of fractures has been available to the orthopaedic community for nearly three decades; however, it is still considered an experimental treatment by some clinicians, even though there is a wealth of clinical data. Based on the evaluation of clinical trial data, we have established key criteria which can lead to LIPUS success and avoid failure. These are fracture gap size and stability, accurate transducer placement and minimum treatment number. However, from a clinician’s view, the correct attitude to treatment must be observed, and this has also been discussed. It is hoped, armed with this new evaluation of the clinical data, that clinicians can treat patients with LIPUS more effectively, resulting in fewer failures of treatment.
- Open Access
Low-intensity pulsed ultrasound (LIPUS) for stimulation of bone healing – A narrative review
- Open Access
- 1 June 2019
- Published by Taylor & Francis in Medical Devices: Evidence and Research
- Vol. ume 12, 227-234
NASHA hyaluronic acid for the treatment of shoulder osteoarthritis: a prospective, single-arm clinical trial
Background: Osteoarthritis of the shoulder or glenohumeral joint is a painful condition that can be debilitating. Intra-articular injection with hyaluronic acid should be considered for patients not responding adequately to physical therapy or anti-inflammatory medication. Methods: This was a single-arm, open-label, prospective study of a single intra-articular injection of NASHA (non-animal hyaluronic acid) in patients with symptomatic glenohumeral osteoarthritis. Patients were followed up for 26 weeks post-treatment, during which time rescue medication with acetaminophen was permissible. The study objective was to demonstrate that a single injection of NASHA is well tolerated with an over-6-month 25% reduction in shoulder pain on movement, assessed using a 100-mm visual analog scale. Results: Forty-one patients were enrolled, all of whom received study treatment. The mean decrease in shoulder pain on movement score over the 6-month study period was −20.1 mm (95% CI: −25.2, −15.0 mm), corresponding to a mean reduction of 29.5% (22.0, 37.0%). Statistically significant improvements were also observed in shoulder pain at night and patient global assessment. There was no clear change over time in the percentage of patients using rescue medication and mean weekly doses were below 3500 mg. Seventeen patients (41.5%) experienced adverse events, all of which were mild or moderate. Two adverse events (both shoulder pain) were deemed related to study treatment. Conclusion: This study provides preliminary evidence that a single injection of NASHA may be efficacious over 6 months and well tolerated in patients with symptomatic glenohumeral osteoarthritis. Larger studies are needed for confirmation.
- 1 June 2019
- Published by Taylor & Francis in Medical Devices: Evidence and Research
- Vol. ume 12, 227-234
Open AccessNASHA hyaluronic acid for the treatment of shoulder osteoarthritis: a prospective, single-arm clinical trial
Background: Osteoarthritis of the shoulder or glenohumeral joint is a painful condition that can be debilitating. Intra-articular injection with hyaluronic acid should be considered for patients not responding adequately to physical therapy or anti-inflammatory medication. Methods: This was a single-arm, open-label, prospective study of a single intra-articular injection of NASHA (non-animal hyaluronic acid) in patients with symptomatic glenohumeral osteoarthritis. Patients were followed up for 26 weeks post-treatment, during which time rescue medication with acetaminophen was permissible. The study objective was to demonstrate that a single injection of NASHA is well tolerated with an over-6-month 25% reduction in shoulder pain on movement, assessed using a 100-mm visual analog scale. Results: Forty-one patients were enrolled, all of whom received study treatment. The mean decrease in shoulder pain on movement score over the 6-month study period was −20.1 mm (95% CI: −25.2, −15.0 mm), corresponding to a mean reduction of 29.5% (22.0, 37.0%). Statistically significant improvements were also observed in shoulder pain at night and patient global assessment. There was no clear change over time in the percentage of patients using rescue medication and mean weekly doses were below 3500 mg. Seventeen patients (41.5%) experienced adverse events, all of which were mild or moderate. Two adverse events (both shoulder pain) were deemed related to study treatment. Conclusion: This study provides preliminary evidence that a single injection of NASHA may be efficacious over 6 months and well tolerated in patients with symptomatic glenohumeral osteoarthritis. Larger studies are needed for confirmation.
- Open Access
- 1 May 2019
- Published by Elsevier in The Journal of Foot and Ankle Surgery
- Vol. 58 (3) , 514-518
Nonanimal Hyaluronic Acid for the Treatment of Ankle Osteoarthritis: AProspective, Single-Arm Cohort Study
- 1 May 2019
- Published by Elsevier in The Journal of Foot and Ankle Surgery
- Vol. 58 (3) , 514-518
Open AccessNonanimal Hyaluronic Acid for the Treatment of Ankle Osteoarthritis: AProspective, Single-Arm Cohort Study
- Top Cited PapersOpen Access
- 1 August 2016
- Published by Elsevier in Ultrasonics
- Vol. 70, 45-52
Mode & mechanism of low intensity pulsed ultrasound (LIPUS) in fracture repair
- 1 August 2016
- Published by Elsevier in Ultrasonics
- Vol. 70, 45-52
Top Cited PapersOpen AccessMode & mechanism of low intensity pulsed ultrasound (LIPUS) in fracture repair